Connect with us

Spread & Containment

Top Analysts Bet on These 3 Penny Stocks; See 100%-Plus Upside Potential

Top Analysts Bet on These 3 Penny Stocks; See 100%-Plus Upside Potential



Penny stocks give a whole new meaning to risk/reward plays. These tickers can witness explosive movements in the blink of an eye, giving them a Street reputation for their high volatility. Any positive development can act as a catalyst that sends shares skyrocketing. The flip-side, however, does hold true, so the risk-averse tend to shy away from these names.

So, how are investors supposed to determine which penny stocks are capable of outperforming the rest? Tracking the analyst community’s activity can be an effective strategy. The pros, who have in-depth knowledge of the industry, offer insight into many names, some of which fly relatively under-the-radar.

Bearing this in mind, we used TipRanks’ database to track down affordable yet compelling plays. We found three penny stocks going for less than $5 apiece with bullish reviews from 5-star Wall Street analysts and over 100% upside potential. Let's take a closer look.

Spectrum Pharmaceuticals (SPPI)

Primarily targeting diseases in hematology and oncology, Spectrum Pharmaceuticals hopes its therapies will be able to address the unmet medical needs of patients. With a $3.08 share price, some analysts believe that now is the ideal time to snap up shares.

Writing for H.C. Wainwright, 5-star analyst Edward White remains focused on its novel long-acting granulocyte colony stimulating factor (GCSF) designed to stimulate neutrophil production for the treatment of chemotherapy induced neutropenia patients, Rolontis. Ahead of the candidate’s October 24 PDUFA date, the analyst highlights that Rolontis isn’t a biosimilar, and calls for 2020 sales of $3 million. Underscoring the huge potential here, he estimates sales will reach $300 million in 2026.

“Pricing in the market seems to be rational with the competition appearing more typical of a branded drug market rather than a generic drug market. Management noted that about 1 million units of GCSF are dispensed per year and that ASP price has been compressing between branded drugs and biosimilars. Despite the COVID-19 pandemic, the company has plenty of inventory available to support the commercial launch of Rolontis,” White commented.

It should also be noted that given the uncertainty surrounding COVID-19, management is planning for both a traditional and a virtual launch. In addition, SPPI is set to have a sufficient sales force on board in time for the commercial launch.

Looking at the clinical trial for Rolontis dosed on the same day as chemotherapy, White argues that the design should bode well for SPPI. “As this is an open-label study, the company can see early data before deciding to continue with development. Though data for a label change are years away, if the data are positive, this study could help dramatically change Rolontis’ market share in the future as we believe same day dosing in a post-COVID-19 world could be a game changer,” he explained.

With ZENITH20 Cohort 1 Poziotinib data at AACR demonstrating “there may be some hope yet”, the deal is sealed for White.

In addition to reiterating a Buy recommendation, he left his price target at $11. This target implies shares could climb 250% higher in the next year. (To watch White’s track record, click here)   

Overall, though not many have weighed in with an opinion on SPPI in the last 3 months, those who have are singing its praises loudly. Overall, two analysts rate the stock a Buy, and the $9.50 average price target puts the potential twelve-month gain at 202%. (See SPPI stock analysis on TipRanks)

Seres Therapeutics (MCRB)

Taking its place at the forefront of microbiome therapeutics, Seres Therapeutics wants to transform the treatment of a wide range of diseases by modulating the function of the human microbiome.

Based on the multiple catalysts slated for 2020 as well as its $4.73 share price, it’s no wonder MCRB is getting glowing reviews from several members of the Street.

Standing squarely in the bull camp is 5-star analyst Gbola Amusa, of Chardan Capital. He points out that enrollment for the Phase 3 ECOSPOR III trial evaluating SER-109's ability to prevent recurrent C. difficile infection (rCDI) is complete, with the candidate already receiving Breakthrough Therapy Designation.

As for the implications of this development, Amusa noted, “With positive results on the expected mid-2022 readout, ECOSPOR III has the potential to be a single pivotal study for the FDA; Seres plans to initiate a SER-109 Expanded Access Program.”

Adding to the good news, the company has taken strides forward when it comes to the advancement of the clinical development for its rationally-designed, fermented microbiome medicine, SER-155, for the prevention of mortality due to gastrointestinal infections, bacteremia and graft versus host disease (GvHD) in immunocompromised patients.

It should be noted that management told investors COVID-19 could impact its SER-287 Phase 2b and SER-401 Phase 1b clinical readouts. This is because the pandemic has put non-essential procedures including endoscopies on hold, and thus, it has been challenging to reach enrollment targets on time. That being said, the company doesn’t believe the availability of its product candidates for ongoing studies will experience any disruptions.

While a potential data readout delay has alarmed some investors, Amusa remains unphased. “Even with Covid-19-related uncertainties on SER-287 and SER-401, we continue to see 2020 as a catalyst rich year for Seres on the ECOSPOR III results alone, which with positive results could lead to SER-109 becoming the first FDA-approved microbiome medicine. Even with recent movements, the current MCRB market cap of $334 million to us is still modest in relation to the risk-adjusted opportunities represented by the pipeline,” he explained.

In line with his optimistic take, Amusa rates MCRB a Buy along with a $12.50 price target. This leaves room for shares to soar 151% in the next year. (To watch Amusa’s track record, click here)     

Do other analysts agree with Amusa? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $9.63, the average price target puts the potential twelve-month gain at 91%. (See MCRB stock analysis on TipRanks)

Akari Therapeutics (AKTX)

Last up to bat we have Akari Therapeutics, which develops innovative treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways. Given its strong execution and share price of only $2.14, is now the right time to get in on the action?

According to B.Riley FBR’s Mayank Mamtani, the answer is a resounding yes. At the end of May, the company provided an update on the progress of the clinical trials for bullous pemphigoid (BP), atopic keratoconjunctivitis (AKC) and pediatric transplant-induced thrombotic microangiopathy (HSCT-TMA) indications for its lead program, nomacopan. The candidate is also getting attention for its potential as a therapeutic option for COVID-19 patients.

The 5-star analyst thinks the full Phase 2 BP study results, as well as an orphan designation granted by the FDA and EMA, free AKTX up to kick off end-of-Phase 2 meetings with the FDA and EMA in Q3 2020 to discuss the pivotal Phase 3 trial design. These meetings would address important considerations including enrolling severe patients in addition to mild and moderate, increasing treatment duration from 1.5 to 6 months, an option to dose at 30 mg-plus levels and a choice of active versus comparator arms, including possibly combining or sequencing with steroids.

“There were no treatment-related serious AEs, in line with the favorable tolerability profile noted in other indications (e.g., PNH), highlighting further differentiation relative to steroid standard of care,” Mamtani stated.

However, Mamtani doesn’t dispute the fact that the COVID-19 pandemic has delayed site initiation activities for the Phase 3 HSCT-TMA trial to later in 2020 and the enrollment for the Part B placebo-controlled efficacy cohort of the Phase 1/2 study in severe AKC patients has been halted. That said, Mamtani notes “the interim update remains on track for mid-2020 in ~2/3rd of the targeted 16 patients already enrolled in the study.” He added, “The prior open-label data of nomacopan eye drops demonstrated in three severe atopic keratoconjunctivitis (AKC) patients rapid overall improvement in composite clinical scores of symptoms and signs.”

On top of this, preclinical data has found complement (C5) and leukotriene (LTB-4) pathways may play a role in severe lung inflammation and microthrombi and organ damage associated with COVID-19. This creates an opportunity for nomacopan as it has been shown to produce a “profound and broad-acting anti-inflammatory effect.”

To wrap it all up, Mamtani commented, “We believe AKTX has held up well in the volatile macro environment as investors look to take advantage of the depressed stock levels for this late-stage biotech supported by robust clinical data generated in earlier-stage trials, with incremental Phase 1/2 severe AKC placebo-controlled data anticipated in mid-2020.”

Everything the company has going for it prompted Mamtani to stay with the bulls. Along with a Buy rating, he kept his $5 price target as is, bringing the upside potential to 134%. (To watch Mamtani’s track record, click here)   

Turning now to the rest of the Street, it has been quiet when it comes to other analyst activity. Mamtani’s call was the only one issued recently.

To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

The post Top Analysts Bet on These 3 Penny Stocks; See 100%-Plus Upside Potential appeared first on TipRanks Financial Blog.

Read More

Continue Reading

Spread & Containment

Russia’s energy war: Putin’s unpredictable actions and looming sanctions could further disrupt oil and gas markets

Russian President Vladimir Putin has not hesitated to use energy as a weapon. An expert on global energy markets analyzes what could come next.




The new Baltic Pipe natural gas pipeline connects Norwegian natural gas fields in the North Sea with Denmark and Poland, offering an alternative to Russian gas. Sean Gallup/Getty Images

Russia’s effort to conscript 300,000 reservists to counter Ukraine’s military advances in Kharkiv has drawn a lot of attention from military and political analysts. But there’s also a potential energy angle. Energy conflicts between Russia and Europe are escalating and likely could worsen as winter approaches.

One might assume that energy workers, who provide fuel and export revenue that Russia desperately needs, are too valuable to the war effort to be conscripted. So far, banking and information technology workers have received an official nod to stay in their jobs.

The situation for oil and gas workers is murkier, including swirling bits of Russian media disinformation about whether the sector will or won’t be targeted for mobilization. Either way, I expect Russia’s oil and gas operations to be destabilized by the next phase of the war.

The explosions in September 2022 that damaged the Nord Stream 1 and 2 gas pipelines from Russia to Europe, and that may have been sabotage, are just the latest developments in this complex and unstable arena. As an analyst of global energy policy, I expect that more energy cutoffs could be in the cards – either directly ordered by the Kremlin to escalate economic pressure on European governments or as a result of new sabotage, or even because shortages of specialized equipment and trained Russian manpower lead to accidents or stoppages.

Dwindling natural gas flows

Russia has significantly reduced natural gas shipments to Europe in an effort to pressure European nations who are siding with Ukraine. In May 2022, the state-owned energy company Gazprom closed a key pipeline that runs through Belarus and Poland.

In June, the company reduced shipments to Germany via the Nord Stream 1 pipeline, which has a capacity of 170 million cubic meters per day, to only 40 million cubic meters per day. A few months later, Gazprom announced that Nord Stream 1 needed repairs and shut it down completely. Now U.S. and European leaders charge that Russia deliberately damaged the pipeline to further disrupt European energy supplies. The timing of the pipeline explosion coincided with the start up of a major new natural gas pipeline from Norway to Poland.

Russia has very limited alternative export infrastructure that can move Siberian natural gas to other customers, like China, so most of the gas it would normally be selling to Europe cannot be shifted to other markets. Natural gas wells in Siberia may need to be taken out of production, or shut in, in energy-speak, which could free up workers for conscription.

European dependence on Russian oil and gas evolved over decades. Now, reducing it is posing hard choices for EU countries.

Restricting Russian oil profits

Russia’s call-up of reservists also includes workers from companies specifically focused on oil. This has led some seasoned analysts to question whether supply disruptions might spread to oil, either by accident or on purpose.

One potential trigger is the Dec. 5, 2022, deadline for the start of phase six of European Union energy sanctions against Russia. Confusion about the package of restrictions and how they will relate to a cap on what buyers will pay for Russian crude oil has muted market volatility so far. But when the measures go into effect, they could initiate a new spike in oil prices.

Under this sanctions package, Europe will completely stop buying seaborne Russian crude oil. This step isn’t as damaging as it sounds, since many buyers in Europe have already shifted to alternative oil sources.

Before Russia invaded Ukraine, it exported roughly 1.4 million barrels per day of crude oil to Europe by sea, divided between Black Sea and Baltic routes. In recent months, European purchases have fallen below 1 million barrels per day. But Russia has actually been able to increase total flows from Black Sea and Baltic ports by redirecting crude oil exports to China, India and Turkey.

Russia has limited access to tankers, insurance and other services associated with moving oil by ship. Until recently, it acquired such services mainly from Europe. The change means that customers like China, India and Turkey have to transfer some of their purchases of Russian oil at sea from Russian-owned or chartered ships to ships sailing under other nations’ flags, whose services might not be covered by the European bans. This process is common and not always illegal, but often is used to evade sanctions by obscuring where shipments from Russia are ending up.

To compensate for this costly process, Russia is discounting its exports by US$40 per barrel. Observers generally assume that whatever Russian crude oil European buyers relinquish this winter will gradually find alternative outlets.

Where is Russian oil going?

The U.S. and its European allies aim to discourage this increased outflow of Russian crude by further limiting Moscow’s access to maritime services, such as tanker chartering, insurance and pilots licensed and trained to handle oil tankers, for any crude oil exports to third parties outside of the G-7 who pay rates above the U.S.-EU price cap. In my view, it will be relatively easy to game this policy and obscure how much Russia’s customers are paying.

On Sept. 9, 2022, the U.S. Treasury Department’s Office of Foreign Assets Control issued new guidance for the Dec. 5 sanctions regime. The policy aims to limit the revenue Russia can earn from its oil while keeping it flowing. It requires that unless buyers of Russian oil can certify that oil cargoes were bought for reduced prices, they will be barred from obtaining European maritime services.

However, this new strategy seems to be failing even before it begins. Denmark is still making Danish pilots available to move tankers through its precarious straits, which are a vital conduit for shipments of Russian crude and refined products. Russia has also found oil tankers that aren’t subject to European oversight to move over a third of the volume that it needs transported, and it will likely obtain more.

Traders have been getting around these sorts of oil sanctions for decades. Tricks of the trade include blending banned oil into other kinds of oil, turning off ship transponders to avoid detection of ship-to-ship transfers, falsifying documentation and delivering oil into and then later out of major storage hubs in remote parts of the globe. This explains why markets have been sanguine about the looming European sanctions deadline.

One fuel at a time

But Russian President Vladimir Putin may have other ideas. Putin has already threatened a larger oil cutoff if the G-7 tries to impose its price cap, warning that Europe will be “as frozen as a wolf’s tail,” referencing a Russian fairy tale.

U.S. officials are counting on the idea that Russia won’t want to damage its oil fields by turning off the taps, which in some cases might create long-term field pressurization problems. In my view, this is poor logic for multiple reasons, including Putin’s proclivity to sacrifice Russia’s economic future for geopolitical goals.

A woman walks past a billboard reading: Stop buying fossil fuels. End the war.
Stand With Ukraine campaign coordinator Svitlana Romanko demonstrates in front of the European Parliament on Sept. 27, 2022. Thierry Monasse/Getty Images

Russia managed to easily throttle back oil production when the COVID-19 pandemic destroyed world oil demand temporarily in 2020, and cutoffs of Russian natural gas exports to Europe have already greatly compromised Gazprom’s commercial future. Such actions show that commercial considerations are not a high priority in the Kremlin’s calculus.

How much oil would come off the market if Putin escalates his energy war? It’s an open question. Global oil demand has fallen sharply in recent months amid high prices and recessionary pressures. The potential loss of 1 million barrels per day of Russian crude oil shipments to Europe is unlikely to jack the price of oil back up the way it did initially in February 2022, when demand was still robust.

Speculators are betting that Putin will want to keep oil flowing to everyone else. China’s Russian crude imports surged as high as 2 million barrels per day following the Ukraine invasion, and India and Turkey are buying significant quantities.

Refined products like diesel fuel are due for further EU sanctions in February 2023. Russia supplies close to 40% of Europe’s diesel fuel at present, so that remains a significant economic lever.

The EU appears to know it must kick dependence on Russian energy completely, but its protected, one-product-at-a-time approach keeps Putin potentially in the driver’s seat. In the U.S., local diesel fuel prices are highly influenced by competition for seaborne cargoes from European buyers. So U.S. East Coast importers could also be in for a bumpy winter.

This article has been updated to reflect conflicting reports about the draft status of Russian oil and gas workers.

Amy Myers Jaffe does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Spread & Containment

Industry groups call to block WTO IP waiver expansion to Covid-19 therapeutics

The WTO’s TRIPS Council in mid-October is expected to debate whether to extend the IP waiver for Covid-19 vaccines to therapeutics and diagnostics too.



The WTO’s TRIPS Council in mid-October is expected to debate whether to extend the IP waiver for Covid-19 vaccines to therapeutics and diagnostics too.

While the Biden administration backed the original vaccine waiver, which critics note has not done much to expand access to vaccines as demand has dried up, US trade officials haven’t offered any perspective yet on whether to expand the waiver to Covid treatments.

The US Chamber of Commerce, as well as industry groups BIO and EFPIA, this week expressed “strong opposition” to any expansion of the WTO TRIPS waiver to therapeutics or diagnostics, arguing that waived IP protections damage the nation’s ability to innovate and compete.

Kevin O’Connor

Illinois-based IP attorney Kevin O’Connor at Neal, Gerber & Eisenberg told Endpoints News in a phone interview that he doesn’t think the vaccine waiver has done much so far.

“I don’t think it was the right solution for a demand problem,” O’Connor said. And an extension to therapeutics “would double down” on the same concept, except small molecule manufacturing is more straightforward than vaccine manufacturing. There’s also the question of whether there is a need for an extension given the voluntary licensing already in place.

BIO also noted that the expansion of a TRIPS waiver to therapeutics can create problems for therapeutics used for other indications too as these other indications “may be their only path to financial viability and sustained investment to fund future R&D initiatives.”

The industry group also noted the lack of a “supply and demand challenge globally that justifies the extension of an IP waiver” considering the fact that manufacturers are supplying therapeutics at a rate that outpaces demand.

The US Chamber of Commerce also noted that in the case of Covid-19 vaccine IP, “the waiver’s realization came long after its ostensible purpose was mooted by a large and growing surplus of COVID-19 vaccine supplies.”

Peter Maybarduk

But Public Citizen’s Peter Maybarduk told Endpoints these are “specious arguments and scare tactics,” adding, “Pharma is worried and that is a good thing for people.”

WTO members and developing countries pledged support for the waiver extension last summer, according to a read out of a meeting. Some even called for this extension to be discussed “with a sense of urgency given the fact that many least developed countries (LDCs) lack access to life-saving drugs and testing therapeutics.”

But other member countries “cautioned that more time was needed to conduct domestic consultations on a possible extension of the waiver to therapeutics and diagnostics” while:

Some members also flagged the importance of an evidence-based negotiation as there was no evidence that intellectual property did indeed constitute a barrier to accessing COVID-19 vaccines. Some also reiterated the need for members to fully make use of all the flexibilities that already exist in the TRIPS Agreement (including compulsory licensing) before requesting new flexibilities.

Read More

Continue Reading

Spread & Containment

Three reasons a weak pound is bad news for the environment

Financial turmoil will make it harder to invest in climate action on a massive scale.




Dragon Claws / shutterstock

The day before new UK chancellor Kwasi Kwarteng’s mini-budget plan for economic growth, a pound would buy you about $1.13. After financial markets rejected the plan, the pound suddenly sunk to around $1.07. Though it has since rallied thanks to major intervention from the Bank of England, the currency remains volatile and far below its value earlier this year.

A lot has been written about how this will affect people’s incomes, the housing market or overall political and economic conditions. But we want to look at why the weak pound is bad news for the UK’s natural environment and its ability to hit climate targets.

1. The low-carbon economy just became a lot more expensive

The fall in sterling’s value partly signals a loss in confidence in the value of UK assets following the unfunded tax commitments contained in the mini-budget. The government’s aim to achieve net zero by 2050 requires substantial public and private investment in energy technologies such as solar and wind as well as carbon storage, insulation and electric cars.

But the loss in investor confidence threatens to derail these investments, because firms may be unwilling to commit the substantial budgets required in an uncertain economic environment. The cost of these investments may also rise as a result of the falling pound because many of the materials and inputs needed for these technologies, such as batteries, are imported and a falling pound increases their prices.

Aerial view of wind farm with forest and fields in background
UK wind power relies on lots of imported parts. Richard Whitcombe / shutterstock

2. High interest rates may rule out large investment

To support the pound and to control inflation, interest rates are expected to rise further. The UK is already experiencing record levels of inflation, fuelled by pandemic-related spending and Russia’s war on Ukraine. Rising consumer prices developed into a full-blown cost of living crisis, with fuel and food poverty, financial hardship and the collapse of businesses looming large on this winter’s horizon.

While the anticipated increase in interest rates might ease the cost of living crisis, it also increases the cost of government borrowing at a time when we rapidly need to increase low-carbon investment for net zero by 2050. The government’s official climate change advisory committee estimates that an additional £4 billion to £6 billion of annual public spending will be needed by 2030.

Some of this money should be raised through carbon taxes. But in reality, at least for as long as the cost of living crisis is ongoing, if the government is serious about green investment it will have to borrow.

Rising interest rates will push up the cost of borrowing relentlessly and present a tough political choice that seemingly pits the environment against economic recovery. As any future incoming government will inherit these same rates, a falling pound threatens to make it much harder to take large-scale, rapid environmental action.

3. Imports will become pricier

In addition to increased supply prices for firms and rising borrowing costs, it will lead to a significant rise in import prices for consumers. Given the UK’s reliance on imports, this is likely to affect prices for food, clothing and manufactured goods.

At the consumer level, this will immediately impact marginal spending as necessary expenditures (housing, energy, basic food and so on) lower the budget available for products such as eco-friendly cleaning products, organic foods or ethically made clothes. Buying “greener” products typically cost a family of four around £2,000 a year.

Instead, people may have to rely on cheaper goods that also come with larger greenhouse gas footprints and wider impacts on the environment through pollution and increased waste. See this calculator for direct comparisons.

Of course, some spending changes will be positive for the environment, for example if people use their cars less or take fewer holidays abroad. However, high-income individuals who will benefit the most from the mini-budget tax cuts will be less affected by the falling pound and they tend to fly more, buy more things, and have multiple cars and bigger homes to heat.

This raises profound questions about inequality and injustice in UK society. Alongside increased fuel poverty and foodbank use, we will see an uptick in the purchasing power of the wealthiest.

What’s next

Interest rate rises increase the cost of servicing government debt as well as the cost of new borrowing. One estimate says that the combined cost to government of the new tax cuts and higher cost of borrowing is around £250 billion. This substantial loss in government income reduces the budget available for climate change mitigation and improvements to infrastructure.

The government’s growth plan also seems to be based on an increased use of fossil fuels through technologies such as fracking. Given the scant evidence for absolutely decoupling economic growth from resource use, the opposition’s “green growth” proposal is also unlikely to decarbonise at the rate required to get to net zero by 2050 and avert catastrophic climate change.

Therefore, rather than increasing the energy and materials going into the economy for the sake of GDP growth, we would argue the UK needs an economic reorientation that questions the need of growth for its own sake and orients it instead towards social equality and ecological sustainability.

The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading